Favorable research on ultrasound contrast was presented at the 13th annual scientific sessions of the American Society of Echocardiography, held this week in Orlando. In one study, Definity was shown to provide a reliable and objective "second opinion" for evaluating cardiac wall motion of difficult-to-image patients when used in conjunction with color kinesis software, according to Definity’s manufacturer, Bristol-Myers Squibb Medical Imaging of North Billerica, MA.
Color kinesis is a new automated prototype process that provides a quantifiable analysis of left ventricular wall motion in patients who require contrast agents to visualize the endocardium, according to researchers from the University of Chicago Hospitals. The software tracks the contrast-enhanced endocardial border and color encodes its motion in real time, the researchers said.
In another study, phase III clinical data of San Diego-based Alliance Pharmaceutical's Imagent agent found that it improved endocardial border delineation, providing a significant improvement in segmental wall-motion (SWM) assessment, according to researchers from the University of Alabama at Birmingham. Imagent also produced a greater than three-fold improvement in SWM scoring accuracy with MRI, the investigators said.
By AuntMinnie.com staff writersJune 13, 2002
Related Reading
Bristol-Myers-Squibb, Amersham Health share patent rights, November 15, 2001
Alliance wins patent interference ruling against Nycomed, September 20, 2001
Alliance closes in on Imavist clearance, August 20, 2001
Nycomed Amersham expands ultrasound efforts as Mallinckrodt exits sector, August 6, 2001
Alliance completes purchase of MBI, January 3, 2001
Copyright © 2002 AuntMinnie.com
